Search - tctmd.com

Displaying 261 - 280 of 342

Sort: Relevancy | Date

News Conference News AHA 2019

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Shelley Wood

November 22, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Daily News

As the US Ages, Uptick Seen in Number of Deaths Due to Heart Disease

Caitlin E. Cox

November 04, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

L.A. McKeown

September 13, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Conference News EuroPCR 2019

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

Michael O'Riordan

May 22, 2019

News Daily News

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

L.A. McKeown

April 23, 2019

News Industry News

VisCardia Announces Completion of Enrollment and Three Month Follow-Up Visits for Its VisONE® Heart Failure Pilot Study

April 22, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

Advertisement

Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure

Dapagliflozin Has Benefits Across Heart Failure Subgroups

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

As the US Ages, Uptick Seen in Number of Deaths Due to Heart Disease

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

VisCardia Announces Completion of Enrollment and Three Month Follow-Up Visits for Its VisONE® Heart Failure Pilot Study

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content